| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 01/02/2007 | US7157616 Genotypically selecting cows which produce milk containing any variant of beta-casein |
| 01/02/2007 | US7157554 Forming a carboxy-saccharide derivative of the glycopeptide antibiotic that has a substituent containing a dicarboxylic acid in which one of the carboxylic acid groups is coupled with a saccharide |
| 01/02/2007 | US7157546 Water-soluble polymer alkanals |
| 01/02/2007 | US7157458 Bifunctional energy-reversible acyl-compositions |
| 01/02/2007 | US7157433 Compounds, compositions as carriers for steroid/nonsteroid anti-inflammatory; antienoplastic and antiviral active molecules |
| 01/02/2007 | US7157420 Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
| 01/02/2007 | US7157418 Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders |
| 01/02/2007 | US7157266 Structure of adenovirus bound to cellular receptor car |
| 01/02/2007 | US7157238 Identifying micrometastsized tissue/masses using double immunoglobulin labeling; immunodiagnostics and cancer detection |
| 01/02/2007 | US7157101 Micronized eplerenone compositions |
| 01/02/2007 | US7157099 Stable, biologically compatible pharmaceutical compositions in the form of water-in-oil microemulsions (w/o), for the sustained release by parenteral administration of active ingredients which are hydrophilic or are made hydrophilic by |
| 01/02/2007 | US7157097 Transdermal or topical mixtures of drugs such as hormones, gelling agents and oleic acid, alcohols or glycols as pentration intensifiers; drug delivery |
| 01/02/2007 | US7157089 A fusion protein containing an antigen of an influenza virus and a bacterial stress protein; vaccines induce a cytolytic T-cell (CTL) response in a mammal |
| 01/02/2007 | US7157087 Modifying selected antibodies with biotin and streptavidin, conjugating these antibodies with an effector molecule, and delivering the conjugated effector to an intracellular target |
| 01/02/2007 | US7157080 Injectable hyaluronic acid derivative with pharmaceuticals/cells |
| 01/02/2007 | CA2445677C Viral inhibition by long-chain alcohols, alkanes, fatty acids and amides |
| 01/02/2007 | CA2436275C Polymeric delivery formulations of leuprolide with improved efficacy |
| 01/02/2007 | CA2417800C Novel microemulsion and micelle systems for solubilizing drugs |
| 01/02/2007 | CA2371550C Ziprasidone suspension |
| 01/02/2007 | CA2368615C Thiadiazolyl urea or thiourea derivatives for antiviral treatment |
| 01/02/2007 | CA2365495C Viral treatment |
| 01/02/2007 | CA2352361C Pharmaceutical combination preparations of carvedilol and hydrochlorothiazide and the process for their preparation |
| 01/02/2007 | CA2339991C Microemulsions as solid dosage forms for oral administration |
| 01/02/2007 | CA2328320C Encapsulated long chain alcohols |
| 01/02/2007 | CA2299511C A pharmaceutical composition having two coating layers |
| 01/02/2007 | CA2283408C Swallow tablet comprising paracetamol |
| 01/02/2007 | CA2236691C Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
| 01/02/2007 | CA2134348C Polysaccharide derivatives and drug carriers |
| 12/30/2006 | CA2551437A1 Method for synthesis of phospholipids-peg-biomolecule conjugates |
| 12/28/2006 | WO2006138735A2 Gel compositions for topical administration |
| 12/28/2006 | WO2006138715A1 Estrogen compositions for vaginal administration |
| 12/28/2006 | WO2006138686A1 Estrogen compositions for vaginal administration |
| 12/28/2006 | WO2006138572A2 Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates |
| 12/28/2006 | WO2006138534A2 Stable warfarin sodium liquid formulation and method of making same |
| 12/28/2006 | WO2006138463A2 Polymer-based compositions and conjugates of non-steroidal anti-inflammatory drugs |
| 12/28/2006 | WO2006138366A2 Protein markers |
| 12/28/2006 | WO2006138035A1 Vehicle for the delivery of topical lipid soluble pharmaceutical agents |
| 12/28/2006 | WO2006137466A1 Pharmaceutical composition |
| 12/28/2006 | WO2006137443A1 Tablet containing hardly soluble active ingredient |
| 12/28/2006 | WO2006137433A1 Aqueous preparation having levocabastine solubilized therein |
| 12/28/2006 | WO2006137289A1 Oil-containing solid and process for producing the same |
| 12/28/2006 | WO2006137222A1 Method for control of drug elution rate and composition for coating of drug-eluting stent |
| 12/28/2006 | WO2006136586A2 N, n-bis- (2-hydroxyethyl) glycine amide as linker in polymer conjugated prodrugs |
| 12/28/2006 | WO2006123031A3 Pharmaceutical composition comprising an oleaginous ointment and vitamin d or the derivatives thereof in solubilised form |
| 12/28/2006 | WO2006111399A8 Highly porous polymeric materials comprising biologically active molecules via covalent grafting |
| 12/28/2006 | WO2006097536A3 Dimeric peptide agonists of the glp-1 receptor |
| 12/28/2006 | WO2006089954A3 Compounds for stabilizing factor vii polypeptide formulations |
| 12/28/2006 | WO2006084211A3 Thermoplastic articles containing a medicament |
| 12/28/2006 | WO2006074397A3 Cripto binding molecules |
| 12/28/2006 | WO2006067577A3 Stable non-dihydrate azithromycin oral suspensions |
| 12/28/2006 | WO2006065455A3 Chewable oral compositions containing an anti-microbial agent and methods of formulating the compositions to have acceptable germ kill properties and taste |
| 12/28/2006 | WO2006031191A8 Compositions comprising compounds capable of forming a reversible bond or association with gaseous nitric oxide |
| 12/28/2006 | WO2006018698A3 Use of cell-specific conjugates for treatment of inflammatory diseases of the gastrointestinal tract |
| 12/28/2006 | WO2006010054A3 Multivalent vla-4 antagonists comprising polyethylene glycol moieties |
| 12/28/2006 | WO2006003518A3 6-phosphorylcholine-n-acetyl-d-galactosamine conjugate molecules and their use in vaccinal, therapeutic and diagnostic applications against bacterial infection of the respiratory tract |
| 12/28/2006 | WO2005110489A3 Nucleic acid aptamers conjugated to high molecular weight steric groups |
| 12/28/2006 | WO2005103231A3 Dentritic cells charged with toxic substances in order to treat kidney cell carcinomas |
| 12/28/2006 | WO2005092390A9 Conjugates of hydroxyalkyl starch and a protein |
| 12/28/2006 | WO2005054295A3 Therapeutic and diagnostic anti-hsp 70 antibodies |
| 12/28/2006 | WO2004041067A3 Prevention and treatment of synucleinopathic disease |
| 12/28/2006 | US20060293327 Composition containing medicine extremely slightly soluble in water being excellent in eluting property and method for preparation thereof |
| 12/28/2006 | US20060293272 RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| 12/28/2006 | US20060293271 RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| 12/28/2006 | US20060293242 Transporting of taxoid derivatives through the blood brain barrier |
| 12/28/2006 | US20060293219 Methods of treating diabetes mellitus |
| 12/28/2006 | US20060292691 RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| 12/28/2006 | US20060292644 Novel tumor-associated marker |
| 12/28/2006 | US20060292204 5,7,3',4'-Tetrahydroxy-5'-C-geranylflavanone (isonymphaeol-B), isolated from an Okinawa propolis; microbiocide, antitumor agent, food, beverage and cosmetic preservative; antioxidant food supplement |
| 12/28/2006 | US20060292198 implanting matrix for bioactive material which is biocompatible porous forms of beta -tricalcium phosphate granules support the development of new bone throughout its structural form, together with bone morphogenic protein as bioactive material |
| 12/28/2006 | US20060292184 Bioadhesive liquid composition which is substantially free of water |
| 12/28/2006 | US20060292133 Use of lactobacillus salivarius |
| 12/28/2006 | US20060292128 Methods of treating schizophrenia |
| 12/28/2006 | US20060292118 Hollow nanoparticles of protein and drug using the same |
| 12/28/2006 | US20060292112 Dendrimer-photosensitizer complexes for medical applications |
| 12/28/2006 | US20060292078 Optical imaging of colorectal cancer |
| 12/28/2006 | DE102005028985A1 Mikroemulsionen und ihr Gebrauch Microemulsions and their use |
| 12/28/2006 | DE102005028696A1 Use of auxiliary material comprising calcium stearate, magnesium stearate, stearic acid, cromoglycic acid and/or di-sodium-cromoglycate, active substance and carrier material, for adjusting abrasion firmness of hardened preparation |
| 12/28/2006 | CA2680945A1 Anti-pdgfralpha antibodies |
| 12/28/2006 | CA2613208A1 N, n-bis- (2-hydroxyethyl) glycine amide as linker in polymer conjugated prodrugs |
| 12/28/2006 | CA2612456A1 Gel compositions for topical administration |
| 12/28/2006 | CA2612415A1 Estrogen compositions for vaginal administration |
| 12/28/2006 | CA2612380A1 Estrogen compositions for vaginal administration |
| 12/28/2006 | CA2612090A1 Tablet containing hardly soluble active ingredient |
| 12/28/2006 | CA2611823A1 Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates |
| 12/27/2006 | EP1736501A1 Peg-functional nucleic acid conjugate |
| 12/27/2006 | EP1736469A2 Processes for the preparation of (R)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-Fluorophenyl)ethyl]-4-piperidinemethanol |
| 12/27/2006 | EP1736163A1 CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| 12/27/2006 | EP1736156A1 STABILIZED 4-AMINO-5-CHLORO-N-¬(1R,3r,5S)-8-METHYL-8- AZABICYCLO¬3.2.1|OCT-3-YL|-2-¬1-METHYLBUT-2-YNYLOXY|-BENZAMIDE CONTAINING COMPOSITION |
| 12/27/2006 | EP1736147A2 Non-chlorofluorocarbon aerosol formulations |
| 12/27/2006 | EP1736144A2 Orally disintegrable tablets |
| 12/27/2006 | EP1736143A1 Process for producing medicine |
| 12/27/2006 | EP1736060A2 Encapsulated agglomeration of microcapsules and method for the preparation thereof |
| 12/27/2006 | EP1735448A2 Inducible dimerization of growth factor receptors for treating cancer |
| 12/27/2006 | EP1735432A1 Cancerous disease modifying antibodies |
| 12/27/2006 | EP1735349A2 Phosphorylcholine conjugates and corresponding antibodies |
| 12/27/2006 | EP1735321A1 Process for preparing rapamycin 42-esters and fk-506 32-esters with dicarboxylic acid, precursors for rapamycin conjugates and antibodies |
| 12/27/2006 | EP1735012A2 Targeting of radioimagining and radiotherapy agents |
| 12/27/2006 | EP1735009A2 iRNA AGENTS TARGETING VEGF |
| 12/27/2006 | EP1735008A2 Tetanus toxin fusion protein for visualization of active synapses |
| 12/27/2006 | EP1735007A2 Cyclodextrin inclusion complexes of pyrimidine-2,4,6-triones |